WO2013066134A3 - 신규한 신남-로다닌 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 - Google Patents

신규한 신남-로다닌 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2013066134A3
WO2013066134A3 PCT/KR2012/009249 KR2012009249W WO2013066134A3 WO 2013066134 A3 WO2013066134 A3 WO 2013066134A3 KR 2012009249 W KR2012009249 W KR 2012009249W WO 2013066134 A3 WO2013066134 A3 WO 2013066134A3
Authority
WO
WIPO (PCT)
Prior art keywords
cinnamyl
pharmaceutical composition
active ingredients
novel
present
Prior art date
Application number
PCT/KR2012/009249
Other languages
English (en)
French (fr)
Other versions
WO2013066134A2 (ko
Inventor
권병목
한동초
한영민
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2013066134A2 publication Critical patent/WO2013066134A2/ko
Publication of WO2013066134A3 publication Critical patent/WO2013066134A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 신남-로다닌 유도체 화합물 또는 이의 약학적으로 허용가능한 염; 및 이를 유효성분으로 포함하는 약학적 조성물에 관한 것이다. 구체적으로, 본 발명의 신남-로다닌 유도체 화합물은 PRL-3(phosphatase of regenerating liver)의 단백질 포스파타제(PPase)의 활성억제를 통하여 암세포의 이동을 억제함으로 암전이 예방 또는 치료에 유용하게 사용될 수 있다. 또한 동일한 기전에 의하여 혈관 내피세포의 이동을 억제하여 혈관신생을 저해함으로 항암제 또는 비정상적 신생혈관 형성으로 야기되는 혈관신생-관련 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2012/009249 2011-11-04 2012-11-05 신규한 신남-로다닌 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 WO2013066134A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0114819 2011-11-04
KR1020110114819A KR101627288B1 (ko) 2011-11-04 2011-11-04 신규한 신남-로다닌 유도체 및 이를 유효성분으로 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2013066134A2 WO2013066134A2 (ko) 2013-05-10
WO2013066134A3 true WO2013066134A3 (ko) 2013-06-27

Family

ID=48192961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/009249 WO2013066134A2 (ko) 2011-11-04 2012-11-05 신규한 신남-로다닌 유도체 및 이를 유효성분으로 포함하는 약학적 조성물

Country Status (2)

Country Link
KR (1) KR101627288B1 (ko)
WO (1) WO2013066134A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109321549B (zh) * 2018-09-18 2021-09-17 天津科技大学 一种比酶活提高的肝素酶i的定向改造酶及分子改造方法和表达工程菌

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004014175A (ja) * 2002-06-04 2004-01-15 Nippon Kayaku Co Ltd 色素増感光電変換素子
WO2004080480A1 (en) * 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
WO2006082245A1 (en) * 2005-02-07 2006-08-10 Novo Nordisk A/S Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH027900A (ja) * 1988-06-27 1990-01-11 Mitsubishi Electric Corp 同期発電機の励磁制御装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004014175A (ja) * 2002-06-04 2004-01-15 Nippon Kayaku Co Ltd 色素増感光電変換素子
WO2004080480A1 (en) * 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
WO2006082245A1 (en) * 2005-02-07 2006-08-10 Novo Nordisk A/S Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOSHIYA NOGUCHI ET AL.: "Synthesis and Structure-Activity Relationships of 5- Phenylthiophenecarboxylic Acid Derivatives as Antirheumatic Agents.", BIOORGANIC & MEDICINAL CHEMISTRY 11., vol. 11, no. 22, 3 November 2003 (2003-11-03), pages 4729 - 4742, XP002992944, DOI: doi:10.1016/j.bmc.2003.08.009 *

Also Published As

Publication number Publication date
KR101627288B1 (ko) 2016-06-03
KR20130049669A (ko) 2013-05-14
WO2013066134A2 (ko) 2013-05-10

Similar Documents

Publication Publication Date Title
PH12018502633A1 (en) Substituted pyridines as inhibitors of dnmt1
BR112015032623A2 (pt) composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
WO2012064150A3 (ko) 벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
MX343753B (es) Inhibidores de neprilisina.
EA201391315A1 (ru) Гуанидиновое соединение
MY184756A (en) Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
ME03016B (me) Derivat piridina
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
BR112014018795A2 (pt) derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
BR112012018253A2 (pt) Derivados de ácido 3-heteroaroilamino-propiônico oxigênio-substituídos e seu uso como fármacos
BR112014001518A2 (pt) derivados de ácido 3-heteroaroilamino-propiônico e seus usos como produtos farmacêuticos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12845878

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12845878

Country of ref document: EP

Kind code of ref document: A2